Repligen Corporation
RGENHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeRepligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The $8.31B market capitalization puts RGEN squarely in mid-cap range for its industry. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Market Cap
$8.31B
Beta
1.06
P/E (TTM)
163.61
P/E (Fwd)
57.72
EPS (TTM)
$0.90
EPS (Fwd)
$2.55
ROE
2.5%
ROA
1.2%
Cash
$784.5M
Total Debt
$687.6M
Free CF
$68.7M
52W Change
26.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $784.5M in cash comfortably exceeding the $687.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $68.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 2.5% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.2% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $670.5M to $738.3M.
At over 50x earnings, RGEN carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing RGEN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.